Predisposition of Wingless Subgroup Medulloblastoma for Primary Tumor Hemorrhage.

BACKGROUND Primary intratumoral hemorrhage as a presenting sign is rare in children with medulloblastomas but may result in severe complications. Given the distinct properties of molecular medulloblastoma subgroups, the impact on neurosurgical practice has still to be defined. OBJECTIVE To investigate both clinical and radiological presentation of intratumoral hemorrhage in medulloblastoma patients in the context of molecular subgroups. METHODS Data of all consecutive medulloblastoma patients treated at our institution between 1993 and 2018 (n = 104) were retrospectively reviewed in respect of clinical and radiological presentation as well as molecular subgroups. For cases with available tumor tissue (n = 86), subgroups were assigned by either 450 K methylation array or immunohistochemistry and CTNNB1 sequencing. Available imaging at diagnosis (n = 62) was reviewed by an experienced neuroradiologist. RESULTS Within the entire cohort, 4 patients (4%) presented with massive spontaneous hemorrhage. Although no patient died as a direct consequence of hemorrhage, all suffered from serious sequelae. Moreover, 3 additional patients displayed radiological evidence of significant hemorrhage. Interestingly, all 7 cases belonged to the wingless (WNT) subgroup (n = 13), resulting in intratumoral hemorrhage in 54% (7/13) of pediatric WNT medulloblastomas. In contrast, significant hemorrhage was absent in all other molecular subgroups. CONCLUSION Our results suggest that a substantial proportion of pediatric WNT medulloblastomas display significant intratumoral hemorrhage at the time of diagnosis. Consequently, the presence of significant hemorrhage in fourth ventricle childhood tumors is suggestive of WNT medulloblastoma and should lead to a less aggressive attempt for total resection in this prognostically favorable tumor type.

[1]  H. Schild,et al.  Imaging Biomarkers for Adult Medulloblastomas: Genetic Entities May Be Identified by Their MR Imaging Radiophenotype , 2017, American Journal of Neuroradiology.

[2]  Sirintra Nakjang,et al.  Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study , 2017, The Lancet. Oncology.

[3]  Roland Eils,et al.  The whole-genome landscape of medulloblastoma subtypes , 2017, Nature.

[4]  A. Goldenberg,et al.  Intertumoral Heterogeneity within Medulloblastoma Subgroups. , 2017, Cancer cell.

[5]  E. Miele,et al.  Anomalous vascularization in a Wnt medulloblastoma: a case report , 2016, BMC Neurology.

[6]  M. Roussel,et al.  Medulloblastoma Genotype Dictates Blood Brain Barrier Phenotype. , 2016, Cancer cell.

[7]  M. Kool,et al.  Risk stratification of childhood medulloblastoma in the molecular era: the current consensus , 2016, Acta Neuropathologica.

[8]  J. Rutka,et al.  Medulloblastoma: Tumor Biology and Relevance to Treatment and Prognosis Paradigm , 2016, Current Neurology and Neuroscience Reports.

[9]  Naoki Kagawa,et al.  Prognostic Value of Medulloblastoma Extent of Resection After Accounting for Molecular Subgroup: An Integrated Clinical and Molecular Analysis , 2016, The Lancet. Oncology.

[10]  D. Ellison,et al.  MR Imaging Characteristics of Wingless-Type–Subgroup Pediatric Medulloblastoma , 2015, American Journal of Neuroradiology.

[11]  Y. Gezercan,et al.  Fatal cerebellar hemorrhage as an initial presentation of medulloblastoma in a child , 2015, Journal of pediatric neurosciences.

[12]  Jill S Barnholtz-Sloan,et al.  Alex's Lemonade Stand Foundation Infant and Childhood Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2007-2011. , 2015, Neuro-oncology.

[13]  Hideo Nakamura,et al.  A patient with medulloblastoma in its early developmental stage. , 2014, Journal of neurosurgery. Pediatrics.

[14]  P. Northcott,et al.  Duration of the pre‐diagnostic interval in medulloblastoma is subgroup dependent , 2014, Pediatric blood & cancer.

[15]  K. Yeom,et al.  MRI Surrogates for Molecular Subgroups of Medulloblastoma , 2014, American Journal of Neuroradiology.

[16]  Volker Hovestadt,et al.  Robust molecular subgrouping and copy-number profiling of medulloblastoma from small amounts of archival tumour material using high-density DNA methylation arrays , 2013, Acta Neuropathologica.

[17]  Axel Benner,et al.  FSTL5 is a marker of poor prognosis in non-WNT/non-SHH medulloblastoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  J. Mesirov,et al.  Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Hendrik Witt,et al.  Medulloblastoma comprises four distinct molecular variants. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Yiai Tong,et al.  Subtypes of medulloblastoma have distinct developmental origins , 2010, Nature.

[21]  Gentian Vyshka,et al.  Sudden death due to medulloblastoma , 2010, BMJ Case Reports.

[22]  Andrew P. McMahon,et al.  Canonical Wnt Signaling Regulates Organ-Specific Assembly and Differentiation of CNS Vasculature , 2008, Science.

[23]  Dirk Troost,et al.  Integrated Genomics Identifies Five Medulloblastoma Subtypes with Distinct Genetic Profiles, Pathway Signatures and Clinicopathological Features , 2008, PloS one.

[24]  E. Rushing,et al.  Undiagnosed medulloblastoma presenting as fatal hemorrhage in a 14-year-old boy: case report and review of the literature , 2007, Child's Nervous System.

[25]  D. Ellison,et al.  Wnt/Wingless Pathway Activation and Chromosome 6 Loss Characterise a Distinct Molecular Sub-Group of Medulloblastomas Associated with a Favourable Prognosis , 2006, Cell cycle.

[26]  T. Merchant,et al.  Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. , 2006, The Lancet. Oncology.

[27]  T. Curran,et al.  Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Claire L Weston,et al.  beta-Catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom Children's Cancer Study Group Brain Tumour Committee. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  H. Clevers,et al.  Wnt signalling in stem cells and cancer , 2005, Nature.

[30]  M. Wolter,et al.  Somatic mutations of WNT/wingless signaling pathway components in primitive neuroectodermal tumors , 2001, International journal of cancer.

[31]  E. Roach,et al.  Nontraumatic Brain Hemorrhage in Children: Etiology and Presentation , 2000, Journal of child neurology.

[32]  L. Becker,et al.  Medulloblastoma: clinical presentation and management. Experience at the hospital for sick children, toronto, 1950-1980. , 1983, Journal of neurosurgery.

[33]  D. Bruce,et al.  Hemorrhagic brain tumors in pediatric patients. , 1981, Child's brain.